Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor

Summary Exposure of MOPC-315 cells from the primary tumor nodule to a low concentration (0.5 nmol/ml) of melphalan (L-phenylalanine mustard; L-PAM) rendered the tumor cells capable of bringing about the generation of a potent primary antitumor cytotoxic response. Accordingly, the level of antitumor cytotoxicity generated by normal spleen cells immunized in vitro with L-PAM-treated tumor cells was at least five-fold greater than the level generated in response to untreated tumor cells. The marked superiority of L-PAM-treated tumor cells over untreated tumor cells in bringing about the generation of antitumor cytotoxicity was evident over a wide range of responder to stimulator cell ratios. The higher level of antitumor cytotoxicity exhibited by normal spleen cells immunized with L-PAM-treated tumor cells as compared with untreated tumor cells was not merely the result of direct drug-mediated tumoricidal activity, thereby reducing the number of tumor cells present which can act as cold target cell inhibitors during the ⁵¹Cr release assay. This is apparent from the observation that the level of antitumor cytotoxicity generated in response to a given percentage of stimulator tumor cells pretreated with 0.5 nmol L-PAM/ml, a drug concentration associated with retention of 60% tumor cell proliferative capacity, is substantially greater than that generated in response to less than half that percentage of untreated stimulator tumor cells. Moreover, stimulator tumor cells exposed to a fully antiproliferative concentration of L-PAM brought about the generation of a higher level of antitumor cytotoxicity than stimulator tumor cells exposed to mitomycin C at a concentration which inhibited the proliferation of the tumor cells to the same extent as the L-PAM. A low concentration of L-PAM which was effective in rendering isolated tumor cells from the primary tumor nodule capable of bringing about the generation of antitumor cytotoxicity was also effective in inducing the appearance of potent antitumor immune potential in tumor bearer splenic cells containing metastatic tumor cells. Thus, metastatic tumor cells within the spleen of tumor-bearing mice may have the potential to act as in situ stimulators for the generation of potent antitumor immunity which brings about the eradication of a large, metastatic tumorigenic load remaining after clearance of the drug from the circulation.Supported by United States Public Health Service Research Grants CA-30088 and CA-35761 from the National Cancer InstituteIn partial fulfillment of the requirements of the Graduate College for the Doctor of Philosophy degree for RCBSBE was visiting Fulbright Professor from the Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Israel, and was supported by the Council for International Exchange of Scholars     

Mechanisms of the antitumor action of spirobromine in mice with leukemia P-388

The influence of new antitumor drug, spirobromine, a derivative of dispirotripiperazine, on DNA synthesis in tumor cells and organs at different times after its injection into mice with P388 leukemia has been studied. The duration of DNA synthesis inhibition in tumor cells was found to correlate with spirobromine antitumor activity. A certain selectivity of action of the studied compound on DNA synthesis in P 388 leukemia cells as compared to the action on DNA synthesis in bone marrow, small intestine, spleen and liver of tumor animals was observed.     

Chloroquine enhances the cytotoxicity of cis-diamminedichloroplatinum II

A low dose (10 microM) of the antitumor drug cis-diamminedichloroplatinum II (cDDP) was not found to be cytotoxic to HeLa S3 cells in culture in this study, as observed by Roberts and Fraval (1978). The cytotoxicity of this nontoxic dose of cDDP, can be greatly enhanced by treating cells with 200 microMs chloroquine immediately after exposure to the platimum drug.     

Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine

4'-(9-acridinylamino) methanesulfon-m-anisidide (amsacrine or AMSA), an antitumor drug which has been tested in clinical trials, is known to bind to DNA by the intercalation of its 9-amino acridine moiety between DNA base pairs. Like AMSA, a peptidic derivative of 4-(9-acridinylamino) aniline, 4-(9-acridinylamino)-N-(lysylglycyl) aniline (ALGA) binds to DNA by intercalation and its affinity for the target was found to be higher than the parent drug. The antitumor effect of AMSA and ALGA has been monitored by drug exposure assays on EMT 6 cells. AMSA showed a slightly higher cytotoxic activity. The cell cycle effects of both drugs were studied using flow cytofluorimetry; an accumulation of cells in the S phase followed by a cycle arrest in the G2 phase, characteristic of intercalating drugs, was observed.     

Dynamic Rearrangement of F-Actin Is Required to Maintain the Antitumor Effect of Trichostatin A

Actin plays a role in various processes in eukaryotic cells, including cell growth and death. We investigated whether the antitumor effect of trichostatin A (TSA) is associated with the dynamic rearrangement of F-actin. TSA is an antitumor drug that induces hyper-acetylation of histones by inhibiting histone deacetylase. HeLa human cervical cancer cells were used to measure the antitumor effect of TSA. The percent cell survival was determined by an MTT assay. Hypodiploid cell formation was assessed by flow cytometry. Collapse of the mitochondrial membrane potential (MMP) was identified by a decrease in the percentage of cells with red MitoProbe J-aggregate (JC-1) fluorescence. Cell survival was reduced by treatment with TSA, as judged by an MTT assay and staining with propidium iodide, FITC-labeled annexin V, or 4′,6-diamidino-2-phenylindole (DAPI). TSA also induced an MMP collapse, as judged by the measurement of intracellular red JC-1 fluorescence. In addition, the F-actin depolymerizers cytochalasin D (CytoD) and latrunculin B (LatB) induced an MMP collapse and increased apoptotic cell death in HeLa cells. However, our data show that apoptotic cell death and the MMP collapse induced by TSA were decreased by the co-treatment of cells with CytoD and LatB. These findings demonstrate that the dynamic rearrangement of F-actin might be necessary for TSA-induced HeLa cell apoptosis involving a TSA-induced MMP collapse. They also suggest that actin cytoskeleton dynamics play an important role in maintaining the therapeutic effects of antitumor agents in tumor cells. They further suggest that maintaining the MMP could be a novel strategy for increasing drug sensitivity in TSA-treated tumors.     

Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipid formulations

Using original technology developed at the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) a drug composition based on plant phospholipids and the antitumor drug doxorubicin (particle size <30 nm) has been developed. In vitro experiments demonstrated that doxorubicin inclusion into the phospholipids nanoparticles decreased drug binding to blood cells and thus increase proportion of the potentially active drug in plasma. This was accompanied by changes in drug redistribution from the plasma protein fraction to high density lipoproteins. Importance of these changes for doxorubicin bioavailability and antitumor activity is discussed.     

Action of ftorafur on the chromosomes of normal and tumorous cells of the Djzungarian hamster in vitro]

The chromosome-breaking effect of antitumor agent ftorafur (0,1 mg/ml) was studied on cell cultures of normal and transformed Djungarian hamster's fibroblasts. After 24 hours of exposition with the drug 79% of aberrant malignant cells was registered, while the chromosomes of normal cells remained undamaged. After ftorafur's action for 2--12 hours and the following removal of the agent the level of aberrant metaphase among normal cells rose to 11--15%. Chromatid breaks were the predominant type of drug-induced aberrations. Thse results confirm the idea that ftorafur blocks the cell cycle of normal fibroblasts and that it's necessary to wash the drug off some period before fuxation in order to reveal its chromosome-breaking effect in metaphase cells. The striking distinctions in susceptibility of normal and malignant cells to the mutagenic effect of ftorafur is partly due to the distrubances of the cell cycle caused by this drug.     

The Improvement of the Anticancer Effect of a Novel Compound Benzoic Acid, 2-Hydroxy-, 2-d-ribofuranosylhydrazide (BHR) Loaded in Solid Lipid Nanoparticles

A novel drug delivery system consisting of benzoic acid, 2-hydroxy-, 2-d-ribofuranosylhydrazide (BHR)-loaded solid lipid nanoparticles (BHR-SLNs) was prepared using the emulsification–evaporation technique. The mean particle size of the BHR-SLNs measured by photon correlation spectroscopy was about 75 nm. BHR-SLN morphology was assessed by transmission electron microscopy and atomic force microscopy. The drug entrapment efficiency was 70.2%, as determined via Sephadex gel chromatography and high-performance liquid chromatography. Drug release assessment in vitro showed that BHR was gradually released from SLNs in a time-dependent manner. Furthermore, treatment of 293T and Hela cells with BHR-SLNs demonstrated that BHR-SLNs were less toxic to normal cells while more effective in antitumor potency compared with the BHR drug alone. The results imply that BHR-SLNs could be considered as a promising antitumor drug system for a range of new therapeutic applications.KEY WORDS: benzoic acid, 2-hydroxy-, 2-d-ribofuranosylhydrazide (BHR); controlled release; drug delivery; solid lipid nanoparticles     

Inhibition of a mouse hepatoma by the alkylating agent trenimon linked to immunoglobulins

Summary Trenimon was conjugated in active alkylating form to rabbit anti-mouse H6 hepatoma globulin (AHG) with retention of antibody activity. H6 hepatoma-inoculated mice were given various combinations of conjugates, free Trenimon, and unconjugated immunoglobulins in daily injections for 5 days. Linkage of Trenimon to immunoglobulins reduced systemic toxicity of the drug, with comparative retention of its antitumor activity. The antitumor action of Trenimon was potentiated by AHG irrespective of whether the drug was directly linked to AHG or free AHG was administered along with Trenimon linked to normal rabbit globulin (NRG).In vitro, Trenimon bound to AHG was less inhibitory to hepatoma cells than free Trenimon, but more inhibitory than Trenimon-NRG conjugates. There was no significant endocytosis of conjugates by the hepatoma cells. This suggests that unlike free Trenimon, the target molecules of Trenimon-immunoglobulin conjugates are not intracellular DNA but are located on the surface of the hepatoma cells.     

Inhibition of initiation of simian virus 40 chromosome synthesis by dihydroxyanthraquinone

The mode of action of dihydroxyanthraquinone, a new antitumor drug, on eucaryotic chromosome structure and function was investigated using simian virus 40 as a model system. Dihydroxyanthraquinone specifically inhibited initiation of viral replicons. Little or no viral DNA synthesis was recovered in cells after the removal of the drug. Elongation and termination of DNA already initiated could proceed continuously to completion in drug-treated cells. The drug appeared to be stably associated with viral chromosomes in cells. The irreversible inhibition of replicon initiation might contribute to its anti-proliferative and anti-neoplastic activity.     

Immune carriers of cytostatics

Summary Chemotherapeutic drugs lack specificity for tumor cells. The specific antitumor action can be acquired by the use of drug-carrying antibodies with specific affinity for tumor cells.Some aspects of this form of immunochemotherapy, such as (a) the antitumor antibody preparation, (b) the effect of the coupling of the drug to the antibody on both the drug and the antibody activity, and (c) future possibilities, are discussed in relation with recent animal and clinical studies.     

The dose-dependent cytogenetic and growth-inhibiting effects of a new antitumor preparation from the nitrosourea group

Kinetics of growth-inhibiting and cytogenetic effect of a new carbon-substituted nitrosourea derivative (ADEKO) has been studied in a wide dose range. A linear dose-effect dependence was observed. The level of damaged cells in a population is connected with a number of chromosomal aberrations per cells with a semilogarithmic dependence. The drug has a pronounced clastogenic effect that reveals itself in total damaging of chromosomal structure of tumor cells. It also causes cell polyploidization with the increase in does and duration of action. Chromosomal aberrations induced by the drug are observed in the tumor long after the action of the drug and their level correlates positively with antitumor activity of ADEKO. ADEKO damages preferentially tumor cells as compared to bone marrow.     

线粒体靶向TPP-DOX连接物的制备及其逆转肿瘤耐药活性研究

目的:阿霉素(DOX)是常用的抗肿瘤药物,但是它的毒副作用大,而且肿瘤细胞易对DOX产生耐药,限制了其临床应用。本研究利用肿瘤细胞线粒体跨膜电位较高的特性,将亲脂性阳离子(3-丙羧基)三苯基溴化膦(TPP)与DOX相连接制备具有线粒体靶向功能的TPP-DOX,以期达到逆转肿瘤细胞耐药的目的。方法:以DOX、TPP为原料,合成TPP-DOX,通过核磁、质谱等方法进行结构鉴定。采用MTT方法研究TPP-DOX对KB细胞、A549细胞及耐DOX肿瘤细胞MDA-MB-231/ADR的体外抗肿瘤活性。采用激光共聚焦显微镜观察TPP-DOX在肿瘤细胞内的分布。结果:TPP-DOX对KB细胞和A549细胞的毒性低于DOX,TPP-DOX对耐DOX肿瘤细胞MDA-MB-231/ADR的毒性明显大于DOX。激光共聚焦显示TPP-DOX分布于细胞核和线粒体中。结论:TPP-DOX具有线粒体靶向特性,可有效逆转肿瘤耐药,有进一步研究的价值。     

Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis

Studying mechanisms of drug antitumor action is complicated by the lack of noninvasive methods enabling direct monitoring of the state and interactions of the drugs within intact viable cells. Here we present a confocal spectral imaging (CSI) technique as a method of overcoming this problem. We applied this method to the examination of localization and interactions of mitoxantrone (1, 4-dihydroxy-5, 8-bis-[([2-(2-hydroxyethyl)-amino]ethyl)amino]-9,10-anthracenedione dihydrochloride), a potent antitumor drug, in living K562 cells. A two-dimensional set of fluorescence spectra of mitoxantrone (MITOX) recorded with micron resolution within a drug-treated cell was analyzed to reveal formation of drug-target complexes and to create the maps of their intracellular distribution. The analysis was based on detailed in vitro modeling of drug-target (DNA, RNA, DNA topoisomerase II) interactions and environmental effects affecting drug fluorescence. MITOX exposed to aqueous intracellular environment, MITOX bound to hydrophobic cellular structures, complexes of MITOX with nucleic acids, as well as the naphtoquinoxaline metabolite of MITOX were simultaneously detected and mapped in K562 cells. These states and complexes are known to be immediately related to the antitumor action of the drug. The results obtained present a basis for the subsequent quantitative analysis of concentration and time-dependent accumulation of free and bound MITOX within different compartments of living cancer cells.     

Investigation of the effect of doxorubicin on the intracellular signaling system

The effect of the antitumor antibiotic doxorubicin on the mechanisms of intracellular signal transduction in the region of free water dispersion has been investigated by the EHF-dielectrometry method. It was shown that the drug whose main target is nuclear DNA has a rather strong influence on free cells of the nucleus, the functions of catecholamine receptors, and the complex of adenylate cyclase with the cytoskeleton. The effect of the drug has significant individual and species differences. Variants of tests for individual selection of doses in the therapeutic practice are suggested.     

Cisplatin-induced imbalances in the pattern of chimeric marker gene expression in HeLa cells.

The effects of the antitumor drug cisplatin on gene expression have been measured during transient transfections in HeLa cells. The results indicate a surprising diversity of response. Expression from two promoters is strongly induced, both in non-replicating plasmids and cellular integrants, whereas expression from two other promoters is strongly inhibited. The results suggest that a drug-induced imbalance in gene expression may contribute to the antitumor properties of cisplatin.     

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Many intercalative antitumor drugs have been shown to induce reversible protein-linked DNA breaks in cultured mammalian cells. Using purified mammalian DNA topoisomerase II, we have demonstrated that the antitumor drugs ellipticine and 2-methyl-9-hydroxyellipticine (2-Me-9-OH-E+) can produce reversible protein-linked DNA breaks in vitro. 2-Me-9-OH-E+ which is more cytotoxic toward L1210 cells and more active against experimental tumors than ellipticine is also more effective in stimulating DNA cleavage in vitro. Similar to the effect of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) on topoisomerase II in vitro, the mechanism of DNA breakage induced by ellipticines is most likely due to the drug stabilization of a cleavable complex formed between topoisomerase II and DNA. Protein denaturant treatment of the cleavable complex results in DNA breakage and covalent linking of one topoisomerase II subunit to each 5'-end of the cleaved DNA. Cleavage sites on pBR322 DNA produced by ellipticine or 2-Me-9-OH-E+ treatment mapped at the same positions. However, many of these cleavage sites are distinctly different from those produced by the antitumor drug m-AMSA which also targets at topoisomerase II. Our results thus suggest that although mammalian DNA topoisomerase II may be a common target of these antitumor drugs, drug-DNA-topoisomerase interactions for different antitumor drugs may be different.     

Synthesis and evaluation of folate-based chlorambucil delivery systems for tumor-targeted chemotherapy

The development of tumor-targeting drug delivery systems, able to selectively transport cytotoxic agents into the tumor site by exploiting subtle morphological and physiological differences between healthy and malignant cells, currently stands as one of the most attractive anticancer strategies used to overcome the selectivity problems of conventional chemotherapy. Owing to frequent overexpression of folate receptors (FRs) on the surface of malignant cells, conjugation of cytotoxic agents to folic acid (FA) via suitable linkers have demonstrated to enhance selective drug delivery to the tumor site. Herein, the chemical synthesis and biological evaluation of two novel folate-conjugates bearing the anticancer agent chlorambucil (CLB) tethered to either an aminoether (4,7,10-trioxa-1,13-tridecanediamine) or a pseudo-β-dipeptide (β-Ala-ED-β-Ala) linker is reported. The two drug delivery systems have been prepared in high overall yields (54% and 34%) through straightforward and versatile synthetic routes. Evaluation of cell specificity was examined using three leukemic cell lines, undifferentiated U937 (not overexpressing FRs, FR(-)), TPA-differentiated U937 (overexpressing FRs, FR(+)), and TK6 (FR(+)) cells. Both conjugates exhibited high specificity only to FR(+) cells (particularly TK6), demonstrating comparable antitumor activity to CLB in its free form. These data confirm the reliability of folate-based drug delivery systems for targeted antitumor therapy; likewise, they lay the foundations for the development of other folate-conjugates with antitumor potential.     

Anticancer efficacies of doxorubicin,verapamil and quercetin on FM3A cells under hyperthermic temperature

Hyperthermia (HT) in combination with anticancer drugs (ACDs) had proven to more efficacious in various cancers, although efficacies vary according to chemotherapeutic compounds and cancer types. Presently there are few data that compares anticancer efficacies among ACDs under hyperthermic conditions. Therefore, we selected three commonly used ACDs (quercetin, verapamil and doxorubicin) and compared their antitumor effects when each was treated with 43°C HT exposure. Firstly, FM3A, a murine breast cancer cell line, was treated with each ACD for 1 h followed by 43°C exposure for additional 1 h, and examined the effects of: 1) each drug, 2) 43°C HT exposure, and 3) the combination of each drug and 43°C HT exposure for 1, 6 and 24 h. The determined overall effects on FM3A cells were arrested cell proliferation, clonogenic efficiency and apoptosis. Pre-treatment of FM3A cells to each ACD followed by 43°C HT exposure produced greater antitumor effects including suppressed cell proliferation, reduced clonogenic efficiency and increased apoptotic cell death, compared to ACD treatment or HT exposure alone. Apoptotic cell death occurred in a time-dependent manner. Among the ACDs, antitumor efficacies varied in the order of doxorubicin > verapamil > quercetin. It was concluded that heat exposure during ACD treatment of caner cells may be an important factor to get a better antitumor benefit, even though this benefit may differ from one drug to another.     

Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog

An albumin-binding prodrug of the extremely potent CC-1065 analog, (+)-FDI-CBI, has been synthesized. This analog, (+)-FDI-CBIM, formed an albumin conjugate when added to human albumin in vitro. A greater amount (>3-fold) of the prodrug can be administered to animals compared to the free drug. The prodrug had significantly improved antitumor efficacy compared to the free drug in animal models using syngeneic animal tumors and human ovarian xenografted tumor cells. Antitumor drug delivery by in situ formation of drug-albumin conjugate is a promising strategy to improve antitumor efficacy.